All In Biotech

Drug Trial Radar · NCT07221084

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Oct 28, 2025

Primary completion

Feb 7, 2026

Study completion Feb 27, 2026

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the PK profile, safety, and tolerability of atumelnant after single and multiple once daily (QD) oral doses in healthy Japanese and Caucasian adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • AtumelnantDrug

    Atumelnant, tablets, once daily by mouth

  • PlaceboDrug

    Placebo, tablets, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (Cmax)Time frame: [Time Frame: Up to Day 30]
  2. Pharmacokinetics (Tmax)Time frame: [Time Frame: Up to Day 30]
  3. Pharmacokinetics (AUC)Time frame: [Time Frame: Up to Day 30]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.